In Reply Dr Baang comments that the HBV reactivation rate of 6.6% with entecavir prophylaxis in our study was relatively higher than the reactivation rate of 1.2% after 5 years of entecavir treatment in patients with chronic HBV in the European Association for the Study of the Liver guidelines.1 We agree that this could be explained by cross-resistance between entecavir and lamivudine. The latter has been extensively used in China, which may cause transmission of lamivudine-resistant viruses in the community.
Lin T, Huang H, Li X. Treatment to Prevent Hepatitis B Virus Reactivation in Patients With Lymphoma Receiving Chemotherapy—Reply. JAMA. 2015;313(12):1270. doi:10.1001/jama.2015.1444